论文部分内容阅读
目的:探讨肺纤方提取物对肺间质纤维化大鼠血管新生的影响。方法:将大鼠分为假手术组、模型组、泼尼松组、氯沙坦组、肺纤方大、中、小剂量组7组,除假手术组外,采用气管插管灌注博莱霉素3mg/kg进行大鼠肺间质纤维化造模;造模第2天予以药物灌胃干预。于14d及28d分两批进行动物处理,免疫组化SP法检测VEGFR1、p38MAPK、PI3K蛋白表达。结果:肺纤方大剂量组均减轻VEGFR1、p38MAPK、PI3K蛋白表达,较模型组差异显著(P<0.05)。结论:肺纤方通过减少肺泡炎及纤维化修复时异常血管新生介导的胶原沉积而具有抗肺间质纤维化作用。
Objective: To investigate the effect of Feixian prescription on angiogenesis in rats with pulmonary interstitial fibrosis. Methods: The rats were divided into sham operation group, model group, prednisone group, losartan group, pulmonary fibrosis large, medium and small dose group 7, except the sham operation group, tracheal intubation perfusion BoLi Mice 3mg / kg rat lung interstitial fibrosis modeling; modeling 2 days to be drug gavage intervention. Animals were treated in two batches on 14d and 28d, and immunohistochemical SP method was used to detect the expression of VEGFR1, p38MAPK and PI3K. Results: Compared with the model group, the Feixian Formula high dose group reduced the expression of VEGFR1, p38MAPK and PI3K significantly (P <0.05). Conclusion: Fei Xian Fang has anti-pulmonary interstitial fibrosis by reducing alveolitis and fibrosis repair abnormal angiogenesis-mediated collagen deposition.